Navigation Links
ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
Date:11/21/2012

SAN DIEGO, Nov. 21, 2012 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced that the dividend to be paid on December 18, 2012, to holders of Chess Depositary Instruments (CDIs) trading on the Australian Securities Exchange will be Australian dollar $0.01636 per CDI. 

(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

ResMed previously declared a quarterly dividend of US dollar $0.17 per share, which had a record date of November 20, 2012, and will be payable on December 18, 2012.  The dividend will be paid in US currency to holders of its common stock trading on the New York Stock Exchange (NYSE). 

The dividend paid in Australian currency to CDI holders reflects the exchange rate on the record date, which was US dollars $1.0389 for each Australian dollar $1.00, and reflects the 10:1 ratio between CDIs and US common shares listed on the NYSE. 

About ResMed
ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Further information can be obtained by contacting Brett Sandercock at ResMed Limited, Sydney, on (+612) 8884-2090; or by visiting the Company's multilingual Website at www.resmed.com

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company's future revenue, earnings or expenses, new product development and new markets for the Company's products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission.  Those reports are available on the Company's Website.


'/>"/>
SOURCE ResMed Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2012
2. ResMed Inc. Announces Record Financial Results For The Quarter And Twelve Months Ended June 30, 2012
3. ResMed Announces Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year-End 2012 Results
4. ResMed Launches Narval™ CC Mandibular Repositioning Device in the US
5. ResMed Inc. Announces Plan To Initiate Dividend And Update On Chief Executive Officer Succession
6. AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock
7. Vasomedical Announces Financial Results for the Third Quarter of 2012
8. Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121
9. Ohr Pharmaceutical Announces Additions to Ophthalmic Scientific Advisory Board
10. NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
11. ShangPharma Announces Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Calif. , March 27, 2017  Cryoport, Inc. ... that it intends to offer shares of common stock ... registration statement on file with the Securities and Exchange ... and other conditions, and there can be no assurance ... completed, or as to the actual size or terms ...
(Date:3/27/2017)... , March 27, 2017 To mark the end ... , Inc., a leader in digital imaging solutions, will showcase ... convention, held at New York,s Jacob ... Your Vision Month, sponsored by the American Optometric Association, is ... importance of receiving comprehensive eye exams. In recognition of this ...
(Date:3/27/2017)... March 27, 2017  Sophiris Bio Inc. (NASDAQ: ... a clinical late-stage biopharmaceutical company developing topsalysin (PRX302) ... today reported fourth quarter and full year 2016 ... Key Corporate Highlights: Advanced ... Cancer. During 2016, the Company reported successful results ...
Breaking Medicine Technology:
(Date:3/28/2017)... , ... March 28, 2017 , ... ... Tri-State Camp Conference in Atlantic City March 13-16, was a busy spot this ... of professional staff discussed strategies for preventing outbreaks among camp communities during the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in ... has a lot to offer to the discussion of dealing with excess skin oil. ... there are many home remedies that can help remove the oily shine while keeping the ...
(Date:3/28/2017)... ... , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. “A ... his parents and teachers had asked of him that he had neglected to do, but ... the Almighty Creator. There were some who would have felt themselves to be special and ...
(Date:3/27/2017)... ... 27, 2017 , ... The respected dental team at Northwood ... without the extensive time commitment and aesthetic disadvantages of traditional braces can now ... custom-designed series of virtually invisible aligners are created for each patient and crafted ...
(Date:3/27/2017)... Plains, NY (PRWEB) , ... March 27, 2017 , ... ... Root Canal Awareness Week by teaching their patients about the key role this treatment ... therapy from an experienced endodontist. To better serve those who need a root ...
Breaking Medicine News(10 mins):